Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

The benefits of antipsychotic medications are sometimes obscured by their adverse effects.
These effects range from relatively minor tolerability issues (eg, mild sedation or dry mouth) …

Rare coding variation has historically provided the most direct connections between gene
function and disease pathogenesis. By meta-analysing the whole exomes of 24,248 …

Mental health symptoms and disorders are common among elite athletes, may have sport
related manifestations within this population and impair performance. Mental health cannot …

Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

BackgroundTreatment-resistant schizophrenia (TRS) is associated with high levels of
functional impairment, healthcare usage and societal costs. Cross-sectional studies may …

Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals
diagnosed with schizophrenia. The identification and management of TRS in clinical …

BackgroundAlthough clozapine is the 'gold standard'for treatment-refractory schizophrenia,
meta-analyses of clozapine for this condition are lacking. AimsWe conducted a systematic …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …